Ney Carter Borges: POAF and Long-Term Outcomes After Cardiac Surgery
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
“Postoperative Atrial Fibrillation (POAF) After Cardiac Surgery.
In a large prospective, multinational cohort (VISION Cardiac Surgery; n = 12,234), new-onset postoperative atrial fibrillation (POAF) occurred in 31.8 percent of patients within 30 days of surgery, confirming its status as the most frequent postoperative complication.
From a prognostic standpoint, POAF was strongly associated with subsequent atrial fibrillation: 6.9 percent versus 0.6 percent, corresponding to an adjusted hazard ratio (aHR) of 11.30 (95 percent CI 8.17–15.70), indicating a more than 10-fold increased risk.
Regarding hard outcomes between 30 days and 1 year:
- The composite of stroke or vascular death occurred in 2.3 percent versus 1.5 percent (aHR 1.32; 95percent CI 0.99–1.77), not reaching statistical significance after adjustment.
- All-cause mortality was significantly higher in POAF patients (3.0 percent versus 1.7 percent), with an aHR of 1.54 (95 percent CI 1.18–2.00).
Importantly, absolute stroke rates remained low (approximately 0.7 percent overall), suggesting that POAF may function more as a risk marker than a direct causal driver of thromboembolic events.
Therapeutic strategies were heterogeneous: only 39.4 percent of POAF patients received oral anticoagulation at discharge, while 48.8 percent were treated with amiodarone, reflecting substantial global variability in management.
Conclusion: POAF is common and clinically meaningful, conferring increased mortality and markedly higher AF recurrence, but with a modest and statistically uncertain impact on thromboembolic outcomes.
These findings highlight the need for individualized risk stratification and more standardized management strategies.”
Other posts featuring Ney Carter Borges on Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering